HPV vaccines: alternative dosage schedules

References

• Gissmann L, Zur Hausen H. Partial characterization of viral DNA from human genital warts (Condylomata acuminata). Int J Cancer. 1980;25(5):605–609.
   PubMed Web of Science ®Google Scholar
• Durst M, Gissmann L, Ikenberg H, et al. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A. 1983;80(12):3812–3815.
   PubMed Web of Science ®Google Scholar
• Boshart M, Gissmann L, Ikenberg H, et al. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. Embo J. 1984;3(5):1151–1157.
   PubMed Web of Science ®Google Scholar
• Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12–23.
   PubMed Web of Science ®Google Scholar
• Tsu VD, Ginsburg O. The investment case for cervical cancer elimination. Int J Gynaecol Obstet. 2017;138(Suppl 1):69–73.
   PubMedGoogle Scholar
• Lee LY, Garland SM. Human papillomavirus vaccination: the population impact. F1000Res. 2017;6:866.
   PubMedGoogle Scholar
• Garland SM, Kjaer SK, Munoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63(4):519–527.
   PubMed Web of Science ®Google Scholar
• Hall MT, Simms KT, Lew JB, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2019;4(1):e19–e27.
   PubMed Web of Science ®Google Scholar
• WHO. Meeting of the strategic advisory group of experts on immunization, October 2018 – conclusions and recommendations. Weekly Epidemiological Record. 2018;93:661–680.
   Google Scholar
• Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(Suppl 5):F123–38.
   PubMed Web of Science ®Google Scholar
• Inglis S, Shaw A, Koenig S. Chapter 11: HPV vaccines: commercial research & development. Vaccine. 2006;24(Suppl 3):S3/99–105.
   PubMedGoogle Scholar
• WHO. Weekly epidemiological record; 2014 May 23. No. 21, 2014, 89, 221–236 2014. Available from: http://www.who.int/wer/2014/wer8921.pdf?ua=1.
   Google Scholar
• Romanowski B, Schwarz TF, Ferguson LM, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011;7(12):1374–1386.
   PubMed Web of Science ®Google Scholar
• Romanowski B, Schwarz TF, Ferguson L, et al. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modeling predictions from a randomized study. Hum Vaccin Immunother. 2016;12(1):20–29.
   PubMed Web of Science ®Google Scholar
• Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793–1802.
   PubMed Web of Science ®Google Scholar
• Ogilvie G, Sauvageau C, Dionne M, et al. Immunogenicity of 2 vs 3 doses of the quadrivalent human papillomavirus vaccine in girls aged 9 to 13 years after 60 months. JAMA. 2017;317(16):1687–1688.
   PubMed Web of Science ®Google Scholar
• Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006 Nov;118(5):2135–2145.
   PubMed Web of Science ®Google Scholar
• Gilca V, Salmeron-Castro J, Sauvageau C, et al. Early use of the HPV 2-dose vaccination schedule: leveraging evidence to support policy for accelerated impact. Vaccine. 2018;36(32Pt A):4800–4805.
   PubMedGoogle Scholar
• Lazcano-Ponce E, Salmeron-Castro J, Garcia-Carranca A, et al. Recommendations for the definition of a policy on vaccination against papillomavirus in Mexico. Strategic advisory group of experts of the World Health Organization. Salud publica de Mexico. 2009;51(4):336–341.
   PubMedGoogle Scholar
• Lazcano-Ponce E, Stanley M, Munoz N, et al. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine. 2014;32(6):725–732.
   PubMed Web of Science ®Google Scholar
• Gilca V, Sauvageau C, Boulianne N, et al. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9–10 year-old girls according to 0–6 month schedule. Hum Vaccin Immunother. 2014;10:8.
   Web of Science ®Google Scholar
• Hernandez-Avila M, Torres-Ibarra L, Stanley M, et al. Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: an epidemiological surveillance mechanism for alternate vaccination schemes. Hum Vaccin Immunother. 2016;12(1):30–38.
   PubMed Web of Science ®Google Scholar
• Kreimer AR, Herrero R, Sampson JN, et al. Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studies. Vaccine. 2018;36:4774–4782.
   PubMed Web of Science ®Google Scholar
• Safaeian M, Sampson JN, Pan Y, et al. Durability of protection afforded by fewer doses of the HPV16/18 vaccine: the CVT trial. J Natl Cancer Inst. 2018;110:2.
   Google Scholar
• Sankaranarayanan R, Prabhu PR, Pawlita M, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol. 2016;17(1):67–77.
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Joshi S, Muwonge R, et al. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. Vaccine. 2018;36(32 Pt A):4783–4791.
   PubMed Web of Science ®Google Scholar
• Radley D, Saah A, Stanley M. Persistent infection with human papillomavirus 16 or 18 is strongly linked with high-grade cervical disease. Hum Vaccin Immunother. 2016;12(3):768–772.
   PubMed Web of Science ®Google Scholar
• Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ. 2014;348:g1458.
   PubMed Web of Science ®Google Scholar
• Palmer T, Wallace L, Pollock KG, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12–13 in Scotland: retrospective population study. BMJ. 2019;365:l1161.
   PubMedGoogle Scholar
• Herweijer E, Leval A, Ploner A, et al. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA. 2014;311(6):597–603.
   PubMed Web of Science ®Google Scholar
• Dominiak-Felden G, Gobbo C, Simondon F. Evaluating the early benefit of quadrivalent HPV vaccine on genital warts in Belgium: a cohort study. PLoS One. 2015;10(7):e0132404.
   PubMed Web of Science ®Google Scholar
• Blomberg M, Dehlendorff C, Sand C, et al. Dose-related differences in effectiveness of human papillomavirus vaccination against genital warts: a nationwide study of 550,000 young girls. Clin Infect Dis. 2015;61(5):676–682.
   PubMed Web of Science ®Google Scholar
• Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032.
   PubMed Web of Science ®Google Scholar
• Kavanagh K, Pollock KG, Cuschieri K, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis. 2017;17(12):1293–1302.
   PubMed Web of Science ®Google Scholar
• Machalek DA, Garland SM, Brotherton JML, et al. Very low prevalence of vaccine human papillomavirus types among 18- to 35-year old australian women 9 years following implementation of vaccination. J Infect Dis. 2018;217(10):1590–1600.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Drolet M, Perez N, et al. Human papillomavirus vaccine effectiveness by number of doses: systematic review of data from national immunization programs. Vaccine. 2018;36(s32Pt A):4806–4815.
   PubMedGoogle Scholar
• Drolet M, Benard E, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565–580.
   PubMed Web of Science ®Google Scholar
• Zeybek B, Lin YL, Kuo YF, et al. The impact of varying numbers of quadrivalent human papillomavirus vaccine doses on anogenital warts in the United States: a database study. J Low Genit Tract Dis. 2018;22:189–194.
   PubMed Web of Science ®Google Scholar
• Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805–814.
   PubMed Web of Science ®Google Scholar
• Hariri S, Schuler MS, Naleway AL, et al. Human papillomavirus vaccine effectiveness against incident genital warts among female health-plan enrollees, United States. Am J Epidemiol. 2018;187(2):298–305.
   PubMed Web of Science ®Google Scholar
• Verdoodt F, Dehlendorff C, Kjaer SK. Dose-related effectiveness of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia: a Danish nationwide cohort study. Clin Infect Dis. 2019.
   PubMed Web of Science ®Google Scholar
• Brotherton JM, Budd A, Rompotis C, et al. Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis. Papillomavirus Res. 2019;8:100177.
   PubMed Web of Science ®Google Scholar
• Scherer EM, Smith RA, Carter JJ, et al. Analysis of memory B-cell responses reveals suboptimal dosing schedule of a licensed vaccine. J Infect Dis. 2018;217(4):572–580.
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Rohrer UH, Kundig TM, et al. The influence of antigen organization on B cell responsiveness. Science. 1993;262(5138):1448–1451.
   PubMed Web of Science ®Google Scholar
• Schiller JT, Lowy DR. Raising expectations for subunit vaccine. J Infect Dis. 2015;211(9):1373–1375.
   PubMed Web of Science ®Google Scholar
• Toh ZQ, Russell FM, Reyburn R, et al. Sustained antibody responses 6 years following 1, 2, or 3 doses of quadrivalent human papillomavirus (HPV) vaccine in adolescent Fijian girls, and subsequent responses to a single dose of bivalent HPV vaccine: a prospective cohort study. Clin Infect Dis. 2017;64(7):852–859.
   PubMed Web of Science ®Google Scholar
• Gilca V, Sauvageau C, Panicker G, et al. Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3–8 years later - an exploratory study. Hum Vaccin Immunother. 2018;1–5.
   PubMed Web of Science ®Google Scholar
• Crotty S, Felgner P, Davies H, et al. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol. 2003;171(10):4969–4973.
   PubMed Web of Science ®Google Scholar
• Gilca V, Sauvageau C, Panicker G, et al. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial. Vaccine. 2018;36(46):7017–7024.
   PubMed Web of Science ®Google Scholar
• Rosberger Z, Steben M, Norris T, et al. A mixed two-dose vaccination schedule: not enough evidence to support a policy change in Quebec. Vaccine. 2019;37(32):4421.
   PubMed Web of Science ®Google Scholar
• Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4(7):e453–63.
   PubMed Web of Science ®Google Scholar